Pharmaceuticals, Biotechnology and Life Sciences
NICE has recommended the use of Takhzyro subcutaneous injection as an option for preventing recurrent attacks of hereditary angioedema (HAE) in people aged 12 and older, within their final appraisal document (FAD), Takeda UK said in a press release Wednesday.
The National Institute for Health and Care Excellence (NICE) has recommended the use of the EUSA Pharma’s targeted cancer immunotherapy, QARZIBA…
English wild-type metastatic colorectal cancer (mCRC) patients are getting more choice to a first-line effective treatment, as the UK National Institute for Health and Care Excellence (NICE) gave a positive Final Appraisal Determination (FAD) recommending the routine National Health Service (NHS) use of Merck’s Erbitux (cetuximab) in combination with either Folfiri or Folfox.
Bristol-Myers Squibb’s closely watched new drug Opdivo, one of the first of a new wave of cancer medicines that boost the immune system, has been rejected as too expensive for treating lung cancer by Britain’s cost watchdog.
The National Institute for Health and Care Excellence (NICE) has published its final recommendations on whether six different drug treatments…
Amgen’s new injectable cholesterol drug Repatha has been turned down for use on Britain’s state health service, underscoring a worldwide debate about the value of such pricey medicines.
A Roche drug that can prolong the lives of some women with advanced breast cancer has been plunged back into the centre of a drug pricing row after Britain’s health cost agency declared that it is still too expensive.